Literature DB >> 25377561

In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology.

Tiziano Barbui1, Alessandra Carobbio1, Elisa Rumi2, Guido Finazzi1, Heinz Gisslinger3, Francesco Rodeghiero4, Maria Luigia Randi5, Alessandro Rambaldi1, Bettina Gisslinger3, Lisa Pieri6, Irene Bertozzi5, Ilaria Casetti2, Animesh Pardanani7, Francesco Passamonti8, Alessandro M Vannucchi6, Ayalew Tefferi7.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25377561     DOI： 10.1182/blood-2014-07-591610

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  40 in total

Review 1.  Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Authors:  Brady L Stein; Jason Gotlib; Murat Arcasoy; Marie Huong Nguyen; Neil Shah; Alison Moliterno; Catriona Jamieson; Daniel A Pollyea; Bart Scott; Martha Wadleigh; Ross Levine; Rami Komrokji; Rebecca Klisovic; Krishna Gundabolu; Patricia Kropf; Meir Wetzler; Stephen T Oh; Raul Ribeiro; Rita Paschal; Sanjay Mohan; Nikolai Podoltsev; Josef Prchal; Moshe Talpaz; David Snyder; Srdan Verstovsek; Ruben A Mesa
Journal:  J Natl Compr Canc Netw       Date:  2015-04       Impact factor: 11.908

Review 2.  Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.

Authors:  Karlyn Martin
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 3.  Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Ayalew Tefferi; Alessandro M Vannucchi; Francesco Passamonti; Richard T Silver; Ronald Hoffman; Srdan Verstovsek; Ruben Mesa; Jean-Jacques Kiladjian; Rȕdiger Hehlmann; Andreas Reiter; Francisco Cervantes; Claire Harrison; Mary Frances Mc Mullin; Hans Carl Hasselbalch; Steffen Koschmieder; Monia Marchetti; Andrea Bacigalupo; Guido Finazzi; Nicolaus Kroeger; Martin Griesshammer; Gunnar Birgegard; Giovanni Barosi
Journal:  Leukemia       Date:  2018-02-27       Impact factor: 11.528

4.  Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.

Authors:  Anders Lindholm Sørensen; Stine Ulrik Mikkelsen; Trine Alma Knudsen; Mads Emil Bjørn; Christen Lykkegaard Andersen; Ole Weis Bjerrum; Nana Brochmann; Dustin Andersen Patel; Lise Mette Rahbek Gjerdrum; Daniel El Fassi; Torben A Kruse; Thomas Stauffer Larsen; Hans Torben Mourits-Andersen; Claus Henrik Nielsen; Christina Ellervik; Niels Pallisgaard; Mads Thomassen; Lasse Kjær; Vibe Skov; Hans Carl Hasselbalch
Journal:  Haematologica       Date:  2019-12-26       Impact factor: 9.941

Review 5.  From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.

Authors:  Alessandro M Vannucchi
Journal:  Haematologica       Date:  2016-11-24       Impact factor: 9.941

6.  A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms.

Authors:  Eva N Hamulyák; Joost G Daams; Frank W G Leebeek; Bart J Biemond; Peter A W Te Boekhorst; Saskia Middeldorp; Mandy N Lauw
Journal:  Blood Adv       Date:  2021-01-12

7.  Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.

Authors:  Tina M Schnöder; Judith Eberhardt; Michael Koehler; Holger B Bierhoff; Sönke Weinert; Akhilesh Datt Pandey; Subbaiah Chary Nimmagadda; Denise Wolleschak; Korinna Jöhrens; Thomas Fischer; Florian H Heidel
Journal:  J Cancer Res Clin Oncol       Date:  2017-02-23       Impact factor: 4.553

Review 8.  Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.

Authors:  Hannah Goulart; John Mascarenhas; Douglas Tremblay
Journal:  Ann Hematol       Date:  2022-03-28       Impact factor: 3.673

9.  Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study.

Authors:  A M Yesilova; S Yavuzer; H Yavuzer; M Cengiz; I D Toprak; E Hanedar; M C Ar; Z Baslar
Journal:  Int J Hematol       Date:  2016-10-03       Impact factor: 2.490

Review 10.  Novel agents for the treatment of polycythemia vera: an insight into preclinical research and early phase clinical trials.

Authors:  Leslie Padrnos; Ruben Mesa
Journal:  Expert Opin Investig Drugs       Date:  2020-07-16       Impact factor: 6.206
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.